Cyproterone acetate (CA) could be a feasible alternative to gonadotropin-releasing analogues (GnRHas) for adolescents undergoing a male-to-female transition, according to new research in the Journal of Sexual Medicine. 

Adding estrogens to the therapy could provide further benefit, the authors said. 

GnRHas are frequently used at the beginning of a transition. But this approach can be expensive, and it's not clear how well it works for patients in late puberty. 

The study involved 27 trans-girls in Belgium who underwent CA therapy for an average of 12 months. At that point, a subgroup of 21 patients added estrogens to their therapy for an average of 16 months. 

During CA therapy alone, over half the participants had decreases in facial hair. About a third started developing breasts. Once estrogens were added, breast development became more common.

More details on the study, including the authors' recommendations, are available here.  

Are you interested in learning more about prosthetic urology and sexual medicine? If so, we recommend the Video Journal of Prosthetic Urology (VJPU).

You'll find a wealth of useful videos covering novel technologies, along with "how I do it" explanations from experts. 

New videos are added regularly. Here are two recent posts: 

• "The Mini-Jupette: An Adjunctive Procedure to Inflatable Penile Prosthesis for Minimal Stress Incontinence Following Radical Prostatectomy" by W. Hellstrom, et al.

• "Alternative Reservoir Placement in Prosthetic Urology" by P. Perito and colleagues.

We encourage you to check out all the videos here. Thinking about submitting a video? You'll find the instructions here.